International Assets Investment Management LLC Grows Position in Danaher Co. (NYSE:DHR)

International Assets Investment Management LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 8.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,067 shares of the conglomerate’s stock after purchasing an additional 80 shares during the period. International Assets Investment Management LLC’s holdings in Danaher were worth $267,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after buying an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after acquiring an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares during the period. Capital International Investors increased its stake in Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares in the last quarter. Finally, Norges Bank acquired a new position in Danaher during the fourth quarter worth $1,752,382,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE DHR opened at $269.31 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $199.47 billion, a PE ratio of 45.65, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. The business’s 50-day moving average price is $260.05 and its 200 day moving average price is $255.10. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the firm posted $2.05 EPS. The company’s revenue was down 2.9% on a year-over-year basis. On average, research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

DHR has been the topic of several research reports. Royal Bank of Canada upped their target price on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Robert W. Baird increased their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. TD Cowen lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.